Colfax Corp. (CFX) Tops Q4 EPS by 5c, Revenues Beat; Offers FY20 EPS Mid-Point Guidance Below Consensus

Colfax Corp. (NYSE: CFX) reported Q4 EPS of $0.61, $0.05 better than the analyst estimate of $0.56. Revenue for the quarter came in at $888 million versus the consensus estimate of $884.28 million.

• Reported $0.24 EPS from continuing operations and achieved $0.61 of adjusted EPS
• Delivered 7.5% year-on-year sales growth in Medical Technology segment including 7.8% organic improvement
• Improved Fabrication Technology operating income and adjusted EBITA margins by over 300 basis points

“We finished a successful and transformative 2019 with another quarter of strong financial performance,” said Matt Trerotola, Colfax President and CEO. “Operating improvements and innovation in our Med Tech platform are returning the business to healthy growth levels. Strong execution in our Fab Tech platform drove global share gain and margin improvement in dynamic market conditions.”

“Our strong organic growth performance demonstrates one of the benefits of our transformed portfolio of businesses. We are now positioned with higher margins, better and less cyclical growth prospects, and improved cash flow potential. We are excited by the many operating and strategic opportunities available to us to create shareholder value.”

GUIDANCE:

Colfax Corp. sees FY2020 EPS of $2.10-$2.20, versus the consensus of $2.19.

For earnings history and earnings-related data on Colfax Corp. (CFX) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Home Depot beats estimates, reaffirms fiscal 2026 guidance